News
VRCA
6.92
+0.29%
0.02
Weekly Report: what happened at VRCA last week (0408-0412)?
Weekly Report · 4d ago
Understanding the Miscommunication: Clarifying Requests for Report Summaries
TipRanks · 04/10 10:55
Weekly Report: what happened at VRCA last week (0401-0405)?
Weekly Report · 04/08 12:00
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. Will present at the 23rd Annual Needham Virtual Healthcare Conference in April 2024. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Ted White, Verrica’s President & Chief Executive Officer, will present.
Barchart · 04/02 06:30
Weekly Report: what happened at VRCA last week (0325-0329)?
Weekly Report · 04/01 11:56
Verrica Pharma gains as FDA lists Ycanth in Orange Book
Healthcare Verrica Pharma gains as FDA lists Ycanth in Orange Book of U.S.-approved therapies. The FDA indicated five years of market exclusivity for its lead product, Y canth. Verrica Pharmaceuticals Inc. (VRCA) stock traded higher on Tuesday.
Seeking Alpha · 03/26 17:33
Verrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Facts
NASDAQ · 03/26 12:10
Verrica Pharmaceuticals' Lead Product, Ycanth, Has Received New Chemical Entity Status And A Listing In The Orange Book From The FDA, Providing A Minimum of Five Years Of Regulatory Exclusivity
Benzinga · 03/26 11:33
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Barchart · 03/26 06:30
Weekly Report: what happened at VRCA last week (0318-0322)?
Weekly Report · 03/25 12:00
Weekly Report: what happened at VRCA last week (0311-0315)?
Weekly Report · 03/18 11:58
Weekly Report: what happened at VRCA last week (0304-0308)?
Weekly Report · 03/11 11:53
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
Kahn Swick & Foti, LLC has commenced an investigation into Verrica Pharmaceuticals Inc. The Company and certain of its executives were sued in a securities class action lawsuit. KSF's investigation is focusing on whether Verrica’s officers and/or directors breached their fiduciary duties.
Barchart · 03/08 17:05
Weekly Report: what happened at VRCA last week (0226-0301)?
Weekly Report · 03/04 11:57
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target
Benzinga · 03/01 13:09
RBC Capital Remains a Buy on Verrica Pharmaceuticals (VRCA)
TipRanks · 03/01 12:28
Verrica Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/01 12:16
Verrica Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 03/01 12:16
HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $13
Benzinga · 03/01 12:07
Buy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansion
TipRanks · 03/01 12:06
More
Webull provides a variety of real-time VRCA stock news. You can receive the latest news about Verrica Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.